Graeme Roy Kaufman
Nessuna posizione attualmente
Storia della carriera di Graeme Roy Kaufman
Precedenti posizioni note di Graeme Roy Kaufman
Società | Posizione | Inizio | Fine |
---|---|---|---|
PARADIGM BIOPHARMACEUTICALS LIMITED | Presidente | 02/05/2014 | 24/06/2020 |
IDT AUSTRALIA LIMITED | Direttore/Membro del Consiglio | 21/11/2017 | 18/11/2019 |
Presidente | 03/10/2013 | 21/11/2017 | |
Independent Dir/Board Member | 01/06/2013 | 21/11/2017 | |
BIONOMICS LIMITED | Direttore/Membro del Consiglio | 18/09/2012 | 31/12/2012 |
Presidente | 31/12/2012 | 08/11/2016 | |
Independent Dir/Board Member | 18/09/2012 | 08/11/2016 | |
ANAGENICS LIMITED | Direttore/Membro del Consiglio | 28/08/2012 | 30/06/2015 |
Independent Dir/Board Member | 27/08/2012 | 30/06/2015 | |
MESOBLAST LIMITED | Corporate Officer/Principal | - | 01/01/2013 |
OPTHEA LIMITED | Direttore/Membro del Consiglio | 30/01/2002 | 25/10/2007 |
CSL LIMITED | Direttore Finanziario/CFO | 01/01/1984 | 01/01/1999 |
ZENYTH THERAPEUTICS LIMITED | Direttore/Membro del Consiglio | - | - |
Formazione di Graeme Roy Kaufman
University of Melbourne | Masters Business Admin |
Statistiche
Distribuzione geografica
Australia | 10 |
Posizioni
Director/Board Member | 5 |
Independent Dir/Board Member | 3 |
Chairman | 3 |
Settori
Health Technology | 8 |
Consumer Non-Durables | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 7 |
---|---|
OPTHEA LIMITED | Health Technology |
CSL LIMITED | Health Technology |
ANAGENICS LIMITED | Consumer Non-Durables |
BIONOMICS LIMITED | Health Technology |
IDT AUSTRALIA LIMITED | Health Technology |
PARADIGM BIOPHARMACEUTICALS LIMITED | Health Technology |
MESOBLAST LIMITED | Health Technology |
Aziende private | 1 |
---|---|
CSL Innovation Pty Ltd.
CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia. | Health Technology |
- Borsa valori
- Insiders
- Graeme Roy Kaufman
- Esperienza